Browsing Chemistry and Biochemistry by Subject "Pharmacology"
Now showing items 1-2 of 2
Investigation Of The Allosteric Modulators Desformylflustrabromine And 4-(2-Hydroxyethyl)-1-Piperazineethanesulfonic Acid (Hepes) Interactions On Nicotinic Acetylcholine ReceptorsNeuronal nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop super family of ligand gated ion channels. Dysregulation of nAChRs can lead to pathologies such as Alzheimer's disease, Parkinson's disease, Autism and nicotine addiction. Possible new therapeutic avenues are positive allosteric modulators (PAMs). The natural product desformylflustrabromine (dFBr), a tryptophan metabolite of the marine bryozoan Flustra foliacea, was found to be PAM of alpha4beta2 nAChR. Evaluation of our synthetic water soluble dFBr salt by two-electrode voltage clamp of Xenopus laevis oocytes expressing human nAChR confirmed that synthetic dFBr displayed similar properties as the natural product. Low concentrations of the synthetic dFBr enhanced ACh's efficacy on alpha4beta2 receptors. At higher dFBr concentrations, dFBr inhibited ACh potentiated responses. On alpha7 receptors, dFBr inhibited ACh induced currents. Further pharmacological characterization of dFBr revealed that dFBr was able to enhance partial agonist potencies and efficacies. Evaluation of dFBr on antagonists showed no effect on antagonist inhibition. The mechanisms of biphasic modulation (potentiation and inhibition) of dFBr on alpha4beta2 nAChR were also investigated. Enhanced efficacy of ACh induced currents by dFBr appeared to be accomplished by dFBr stabilization of the open receptor conformation by destabilization of the desensitized state. The inhibition of ACh potentiated currents by dFBr appeared to involve open-channel block. To better understand dFBr mechanisms, its putative binding site was examined. Alanine mutations were made in non-orthosteric clefts on the beta2+ and alpha4- faces. Results revealed residues located on these faces are involved in ACh induced conformational change of the receptor. In addition our data supports our hypothesis that allosteric modulation by dFBr interacts with residues located on the beta2+ and alpha4- faces. The new novel actions of (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) as a alpha4beta2 stoichiometric PAM was discovered and characterized. We showed that HEPES, a common buffering agent, potentiated the high ACh sensitivity alpha4beta2 receptor while only inhibiting the low ACh sensitivity alpha4beta2 receptor. Mutagenesis results suggested that residue beta2D217 is a critical residue in the HEPES binding site. Results from these studies will aid in the development of therapeutic ligands that will assist in the treatment of diseases where nAChRs are dysregulated.
Pharmacology Of A Novel Class Of Allosteric Modulators For The Alpha4 Beta2 Sub-Type Of Neuronal Nicotinic Acetylcholine ReceptorsNeuronal nicotinic acetylcholine receptors (nAChRs) are members of a large family of ligand gated ion channels that mediate inhibitory and excitatory neural transmission in the central nervous system (CNS). The nicotinic subfamily has been implicated in a range of neurological disorders including autism, Alzheimer's disease and nicotine addiction; diseases that are currently both challenging and costly to treat. Despite the apparent importance of nAChRs in these disorders, only a limited number of drugs are currently available for altering nicotinic signalling in the CNS. No drug therapies are currently available that specifically target autism and only a limited number of drugs are available for the treatment of Alzheimer's disease. This thesis presents a novel class of nAChR ligands based on the natural product desformylflustrabromine (dFBr). Desformylflustrabromine (dFBr), a metabolite of the marine bryozoan Flustra Foliacea, was previously identified as an allosteric modulator of the alpha4beta2 subtype of nAChRs. In collaboration with Dr. Richard Glennon at the Virginia Commonwealth University, College of Pharmacy, we developed a synthetic dFBr and evaluated its interaction with two of the most common subtypes of nAChRS, alpha7 and alpha4beta2 (Chapter 2). We confirmed that dFBr is the active component of Flustra Foliacea and identified an additional inhibitory action that becomes evident as dFBr concentrations are increased beyond 10muM. This inhibition was not previously reported. Synthetic dFBr appears significantly more potent at potentiation of alpha4beta2 receptors then reported for the natural extract and shows only inhibitory action on alpha7 receptors. Multiple analogues of dFBr were designed and synthesized to determine the structure activity relation (SAR) for dFBr's action on alpha4beta2 receptors (Chapter 3). We identified three analogues capable of potentiating responses of acetylcholine. The majority of compounds inhibited responses on both alpha4beta2 and alpha7 receptors. The data presented here provide important information for determining a preliminary pharmacophore for dFBr and provide direction for the design of additional analogues on the path to development of more potent and potentially therapeutically useful analogues. To better understand the relationship of dFBr to other nAChR modulators, we also compared the action of dFBr to that of physostigmine, zinc and 17 beta-estradiol (Chapter 4). These compounds are thought to act at three different binding sites on nAChRs. All three compounds increase responses of alpha4beta2 receptors to acetylcholine. Our data show that dFBr is distinct from the clinically used modulator physostigmine but suggests similarities in mechanism with zinc and 17-beta-estradiol. These data provide important information regarding the mechanism of dFBr modulation and provide direction for future site directed mutagenesis studies that will identify the dFBr binding site. Identification of the binding site is critical for the development of receptor models that will facilitate computer assisted drug design.